Drug-labels.com

Sialor Product Monograph

Strength:
25.0 mg
Active ingredient:

Product Monograph - Sialor

ACTION AND CLINICAL PHARMACOLOGY

In addition to its choleretic activity, anetholtrithion has a positive effect on drug induced asialias which may be due to the drug's direct action on the secretory cells of the salivary glands.

Approximately 30% of an orally administered dose is absorbed from the gastrointestinal tract, with

80% being excreted in the urine and the remainder in the bile.

In man, the average amounts of anetholtrithion recovered as the free

p-hydroxyphenyltrithione metabolite or its o-glucuronide are 1.5 to 3 and 12%, respectively. The yellow colouration of the urine resulting from anetholtrithion ingestion is due to the presence of the

2 metabolites.

INDICATIONS

The treatment of oral symptoms of xerostomia in order to reverse drug-induced hyposialosis related to the administration of certain drugs (neuroleptics, tranquilizers, antidepressants, synthetic antiparkinsonian agents) or following a course ofradiotherapy ofthe head and neck area.

CONTRAINDICATIONS

Jaundice, cirrhosis, biliary tract or common bile duct obstruction.

PRECAUTIONS

Rarely, soft stools may be produced. If this persists, reduce the dosage to 25 mg in the morning and

25 mg in the evening.

Pregnancy and Lactation:

Anetholtrithion!s safety for use in human pregnancy has not been established. Therefore, the drug should not be used in pregnancy or lactation unless its use is deemed essential to the welfare of the mother and/or fetus.

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Symptomatic: gastric lavage, induce diuresis.

DOSAGE AND ADMINISTRATION

25 mg 3 times a day before meals. Treatment may be continuous or intermittent with 5 drug free days/month in association with the drugs responsible for the asialia. In hyposialosis related to radiotherapy, administration may be continued indefinitely. Usually, anetholtrithion's full therapeutic effect is gradually achieved after several days of treatment.

AVAILABILITY

Each orange-red, sugar coated tablet contains: anetholtrithion 25 mg. Sunset Yellow and Carmine

Red dyes are used in the tablet coating. Boxes of 60.

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02240344

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Sialor

DIN 02240344
Schedule(s) ETHICAL
Active ingredient(s) Anethole trithione 25 MG
Dosage form(s) Tablet
Route(s) of administration Oral
Drug class (WHO ATC)
  1. A Alimentary tract and metabolism drugs
    1. A16 Other alimentary tract and metabolism products
      1. A16A Other alimentary tract and metabolism products
        1. A16AX Various alimentary tract and metabolism products
          1. A16AX02 Anethole trithione
Company PHARMASCIENCE INC
Current status Marketed
Current status date March 31, 2005

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.